← Issue №18/ week of Nov 1, 2026/ the whole section, in full

Colorectal, in full.

All 6 Colorectal papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 6, in full

most clinically useful first · the 1 the issue led with is ruled in green
Colorectal meta analysis · n=761 · Oct 27, 2026 · Ann Intern Med · IF 19.6

Laparoscopic Versus Open Liver Resection for Colorectal Liver Metastases : An Individual Participant Data Meta-analysis of Four Randomized Clinical Trials.

New evidencecolorectal surgerymeta-analysissystematic reviewhealth services
What it foundLaparoscopic liver resection for colorectal metastases reduced postoperative morbidity to 19% versus 27% for open resection, with no difference in overall or disease-free survival at a median 93-month follow-up. However, 90-day mortality was higher in the laparoscopic group (1.8%) compared to the open group (0.8%).
ContextThis literature reports that laparoscopic liver resection (LLR) and open liver resection (OLR) for colorectal liver metastases (CRLM) are compared in terms of postoperative and long-term oncologic outcomes, with ongoing evaluation of subgroup effects.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Olij B … LLR vs OLR IPDMA Collaborators · Annals of Internal Medicine · IF 19.6 · PubMed ↗Permalink
Colorectal review · Oct 28, 2026 · Am J Gastro · IF 9.8

Preventing Clostridioides difficile Infection and Recurrence: Practical Strategies for Clinical Practice.

Guideline / reviewmicrobiomesystematic reviewguideline
Clinical takeawayConsider extended antibiotic regimens, oral vancomycin prophylaxis during subsequent systemic antibiotic exposure, and microbiome restoration therapies for patients with CDI, especially those at high risk of recurrence (older adults, immunocompromised individuals, transplant recipients, and patients with IBD), while monitoring for potential adverse events.
What it foundExtended antibiotic regimens, oral vancomycin prophylaxis during systemic antibiotic exposure, and microbiome restoration therapies (e.g., fecal microbiota transplantation or FDA-approved microbiota-based therapies) reduce recurrent Clostridioides difficile infection (rCDI) compared to standard care.
ContextThis review confirms and refines current strategies for preventing CDI and rCDI, emphasizing microbiome preservation and restoration as central to reducing recurrence.
Measured against the standard of care· AGA Clinical Practice Update (Expert Review) on CDI in Adults, Clin Gastroenterol Hepatol 2026 / AGA Clinical Practice Update on CDI in IBD, Gastroenterology 2026 / ACG 2021 (superseded where they conflict)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Two 2026 AGA expert reviews now take precedence over the ACG 2021 guideline on several points. They are the AGA Clinical Practice Update on CDI in adults (Clin Gastroenterol Hepatol 2026; 14 best practice advice statements) and the AGA update on CDI in IBD (Gastroenterology 2026; 12 statements). Neither grades its statements with GRADE. DIAGNOSIS: CDI is a clinical diagnosis that needs compatible symptoms (about 3 or more unformed stools in 24 h) plus supportive lab testing. A multistep algorithm is preferred: a sensitive test (GDH or NAAT), then toxin EIA. A NAAT+/EIA- result should be read with caution, and patients with discordant results but high clinical suspicion should still be treated. SEVERITY: classify hospitalized patients at diagnosis. Severe is WBC >15,000/µL and/or creatinine >1.5 (ACG: >1.5 mg/dL; one secondary summary of the AGA text reports >1.5 times baseline). Fulminant is shock, ileus, or megacolon. INITIAL NONFULMINANT EPISODE (nonsevere or severe): fidaxomicin 200 mg twice daily for 10 days is favored first-line because of its narrower spectrum and lower recurrence. Oral vancomycin 125 mg four times daily for 10 days is an acceptable alternative. Metronidazole should not be used outside fulminant disease, which removes the ACG 2021 low-risk metronidazole option. Do not use cholestyramine or other bile-acid binders as monotherapy or alongside vancomycin or fidaxomicin. FULMINANT: manage with a multidisciplinary team. Give oral or enteral vancomycin 500 mg every 6 hours plus IV metronidazole 500 mg every 8 hours, and add rectal vancomycin 500 mg every 6 hours if ileus is present. Consider multi-dose FMT by lower endoscopy. The licensed products (fecal microbiota, live-jslm; fecal microbiota spores, live-brpk) are not approved for severe or fulminant CDI. After severe or fulminant CDI, keep the patient on suppressive vancomycin until a final outpatient FMT. FIRST RECURRENCE (within 8 weeks of finishing therapy): tapering/pulsed vancomycin or fidaxomicin, plus a recurrence-risk assessment and consideration of microbiota restoration. MICROBIOTA-BASED THERAPY (FMT or the licensed products): offer after treatment of a second recurrence. Consider it after an initial episode or first recurrence in patients at high risk of further recurrence or with a severe or refractory episode. SUPPRESSION: consider prolonged low-dose vancomycin 125 mg daily for patients with multiple recurrences who cannot receive or have failed microbiota-based therapy, have limited life expectancy or ongoing comorbidities, or need frequent systemic antibiotics. PREVENTION: do not use vancomycin prophylaxis during systemic antibiotics in the general population. Do not use probiotics for primary or secondary prevention. Encourage a high-fiber diet. Do not stop a PPI that has a legitimate indication, but review its use. Counsel patients with prior CDI to avoid unnecessary antibiotics. Use barrier precautions and EPA-approved sporicidal disinfection. No routine test of cure: retest only for persistent or worsening diarrhea. Bezlotoxumab does not appear in the AGA statements (Merck discontinued it in January 2025). IBD (AGA 2026): test for CDI in IBD patients with new or worsening diarrhea, including those with a pouch or ileostomy, using a multistep toxin-based assay. Treat a first episode preferentially with fidaxomicin, or vancomycin if fidaxomicin is unavailable or too costly. Never use metronidazole. Continue necessary IBD immunosuppression during CDI, and steroids may be used if needed. If symptoms persist after 48-72 h of treatment, consider endoscopy to assess IBD activity and CMV. Offer microbiome-based therapy after at least one recurrence. No probiotics. Oral vancomycin prophylaxis may be considered during systemic antibiotics in IBD patients with prior CDI. The summaries reviewed did not mention the ACG 14-day minimum vancomycin course in IBD.

AGA Clinical Practice Update (Expert Review) on CDI in Adults, Clin Gastroenterol Hepatol 2026 / AGA Clinical Practice Update on CDI in IBD, Gastroenterology 2026 / ACG 2021 (superseded where they conflict) · reviewed 2026-10-11 ↗
Axelrad JE, Allegretti JR · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Colorectal retrospective · n=7,555 · Oct 29, 2026 · Dis Colon Rectum · IF 3.5

Impact of Emergent Inpatient Hospital Utilization among Rectal Prolapse Patients: A Nationwide Cohort Analysis.

New evidenceepidemiologyhealth servicescolorectal surgery
Clinical takeawayConsider proactive multidisciplinary management, including early surgical referral, for patients with rectal prolapse, particularly those with socioeconomic vulnerability, multimorbidity, or psychiatric/cognitive conditions, to reduce emergent admissions and improve outcomes. Note that diagnoses and procedures were identified using administrative billing codes, which may limit accuracy.
What it foundEmergent admissions for rectal prolapse accounted for 22.2% of cases and were associated with longer length of stay, higher in-hospital mortality, and lower likelihood of discharge home compared to elective admissions.
ContextThis study highlights disparities in healthcare utilization and outcomes for rectal prolapse patients, challenging the current focus on elective management by identifying a significant subset requiring emergent care.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Zeineddine JH … Cauley CM · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
Colorectal retrospective · n=189,829 · Nov 1, 2026 · Colorectal Disease · IF 3.2

Outcome-specific risk factors for dehydration and acute kidney injury readmission after ileostomy: A US National Cohort Study, 2016-2022.

New evidenceepidemiologyhealth servicescost-effectivenesscolorectal surgery
Clinical takeawayConsider risk-stratified discharge protocols for ileostomy patients, incorporating community stoma-output monitoring, especially for those with extended hospital stays (>7 days), complicated diabetes, or age ≥65 years.
What it foundHome discharge increased dehydration-specific readmission (aOR 1.25) but decreased AKI-specific readmission (aOR 0.92), with strongest risk factors being extended length of stay >7 days (aOR 1.48), complicated diabetes (aOR 1.46), and age ≥65 years (aOR 1.46).
ContextThis study challenges the assumption that home discharge uniformly reduces readmission risks after ileostomy, highlighting divergent outcomes for dehydration and AKI, and identifies specific risk factors not previously quantified at a national level.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Nigam A … Harmon JV · Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland · IF 3.2 · PubMed ↗Permalink
Colorectal retrospective · n=734 · Oct 29, 2026 · Am J Gastro · IF 9.8

Metachronous Advanced Neoplasia in Early Onset Colorectal Cancer.

New evidencecolorectal cancercolorectal cancer screeningadenomadysplasia
Clinical takeawayNo clinical action yet: this retrospective study does not support altering surveillance intervals for early-onset colorectal cancer (EOCRC) based on MAN risk alone.
What it foundMetachronous advanced neoplasia (MAN) rates were similar in early-onset (13%) and average-onset (16.1%) colorectal cancer patients (p = 0.342).
ContextChallenges the assumption that EOCRC patients require more intensive surveillance than average-onset CRC patients, as MAN rates were comparable.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Naseem Z … Burke CA · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
Colorectal prospective cohort · n=95 · Nov 1, 2026 · Colorectal Disease · IF 3.2

Predicting LARS with POLARS: Results of a multicentre study.

New evidencecolorectal surgery
Clinical takeawayUse POLARS cautiously to identify patients at elevated risk of major LARS, but combine it with clinical judgement and patient-reported follow-up for accurate prediction.
What it foundPOLARS predicted major LARS with 29.2% sensitivity and 80.3% specificity, systematically overestimating severity (mean bias +7.99 points). The POLARS scoring questionnaire was used preoperatively, and LARS scoring questionnaire was used postoperatively.
ContextPOLARS adds a preoperative tool for predicting LARS in patients undergoing rectal resection with low pelvic anastomosis, but its weak correlation (rho = 0.21) and low sensitivity challenge its standalone utility in current practice.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Klimovskij M … Dulskas A · Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland · IF 3.2 · PubMed ↗Permalink
← Back to issue №18 Every section of this issue is one click away, at the top of this page. Follow Colorectal by RSS